🎥 LIVE from #ACR25 Join us daily at 5 PM CST for RheumNow’s ACR Recap Live - Your must-watch debrief of the day’s biggest breakthroughs, hot abstracts, and real-time clinical takeaways. Streaming on YouTube Live, Facebook Live, X-Live & LinkedIn Live. Save the time. Be part of https://t.co/xn4yUta9Da

In a global retrospective study of 90,536 PsA patients, those on GLP-1 receptor agonists (n=4,104) had significantly lower risk of major cardiovascular events and reduced mortality vs non-users. Most common GLP-1 RA: semaglutide. Supports future research on cardiometabolic https://t.co/ccOL10gD5b

Time for the 2nd plenary session! 🎤 #0849 GLP-1 receptor agonists in #PsA linked with lower mortality & fewer major cardiac events in >90K patients. Promising data for inflammation, weight & heart health in PsA care. @RheumNow #ACR25 https://t.co/8zyrSrumOP

This morning in the plenary, same theme, but in PsA: Similar metabolic/CV concerns Similarly benefit from GLP-1 RA looking at TriNetX data again, reduced MACE Now prospective trials in rheum disease, for both metabolic benefits & disease activity? #ACR25 ABST0849 @RheumNow https://t.co/DHZN1hwbIG

GLP-1 RA meds: we are just starting to see their impact in rheumatoid arthritis. We know metabolic, CV risk in RA, but what to do? RA pts in TriNetX, obese non-diabetic GLP-1 RA reduced 1y CV events & also all-cause mortality Soon will be near-standard #ACR25 ABST0445 @RheumNow https://t.co/4ptAHdmf9q

Key slide and takeaways on the ACR 2025 extrarenal SLE guideline. Presented by Lisa Sammaritano @RheumNow #ACR25 #ACRBest https://t.co/Xa97O6RdBY

Crisci et al. from CorEvitas. Alcohol, esp moderate use, associated lower CDAI. Most likely explanation appears to be residual confounders based on impact of adjustments however... @RheumNow #ACR25 Abstr#1340 https://t.co/cd0JLW8nGD

#ACR25 Abstr#0773 Anti-MDA5 ab is assoc. with progressive DM-ILD. But MDA5 expression is also upregulated in IPF. Any new biomarker which can link these ILD? Measuring reactivity to MDA5 (aa 201-300) epitope peptide may help identify poor ILD prognostics (with/out DM) @RheumNow https://t.co/rziwihKfIr

What is the #frequency of #CTD #ILD in #USA? Data from #Marketscan >9K & #Optum ~20k CTD-ILD Pts 56-65 yrs, 3/4 F ?under ascertained #RA-ILD - low % but #SSc-ILD approx 16% clinically relevant Same as Ont, Canada #SSc-ILD % Not rare #ACR25 @RheumNow @ACRheum Abst#0154 https://t.co/imfSyOtYpC

Increased risk of psoriatic arthritis with obesity. A preview to Abstract#2687 Scher J @RheumNow #ACR25 https://t.co/cMbrQnq8YG

High prevalence of sleep related symptoms in PsA pts! -Snoring 53% -Morning fatigue 68% -Obstructive Sleep Apnea in 50% 14% mild 19% moderate 17% severe Estimated prevalence 36% No correlation between OSA and PsA disease activity or comorbidities But small cohort! https://t.co/VKe7qcHIRm

#ACR25 Abstr#663 “Off-the-Shelf” iPSC-derived CAR-T is coming soon! Promising data on 8 #SLE patients in Phase 1. Advantages over autologous/allogenic: -No apheresis -No conditioning chemo -Shorter hospital stays ~3 days -Ability to redose in partial responder @RheumNow https://t.co/pbem7A5Iq5

Dr. Ogdie on emerging PsA tx: “It’s not just about the pharmacotherapy but also about making the patient feel better” Also, weight loss is incredibly important but also incredibly hard. Losing weight is more impt than the type of diet a patient should be on. #ACR25 @RheumNow https://t.co/FN3EEowkDP

Why do we need to identify early PsA? 🔅Improve symptoms 🔅Prevent radiographic progression 🔅Preserve function ☝️Recent data show that erosions are prevalent in early PsA but lower if symptom duration is <6 mos. #ACR25 @RheumNow https://t.co/sEGXzd8RiD